跳至主要内容
临床试验/NCT01207674
NCT01207674已完成不适用

Transversal Multiaxial Evaluation and 5-year Follow-up of a Cohort of French Gamblers.

Nantes University Hospital8 个研究点 分布在 1 个国家目标入组 641 人开始时间: 2009年4月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
641
试验地点
8
主要终点
Number of psychiatric comorbidities

研究概览

简要总结

This study is divided into two stages. The first stage is a transversal study and corresponds to the recruitment of participants, which will last about two years. Three groups of gamblers will be constituted : Non-problematic gamblers (NPG), Problematic gamblers Not in Care (PGNC) and Problematic gamblers in Care (PGC).The second stage is a prospective 5-year follow-up study of the cohort (only the initial NPG and PGNC groups are concerned by the follow-up study), that consists on an annual follow-up evaluation. The main objective of the first stage of the study is to compare the characteristics of the three groups of gamblers on some socio-demographic and clinical data. These comparisons will allow us to identify, among all data, those that will be most likely to explain the evolution of the practice of gambling (appearance or resolution of a gambling problem), and recourse to specific care. These such isolated data will be tested in the second stage of the study, in order to determine those that are predictive factors of three steps of the gambling course of some gamblers : evolution of a controlled gambling practice into a problematic gambling practice, resolution of the problematic gambling practice without intervention of care, and first recourse to specific care.

研究设计

研究类型
Interventional
分配方式
Non Randomized
主要目的
Other

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • To be 18 to 65 years old
  • To have gambled during the last year
  • To gamble at least one time a year

排除标准

  • To be under tutelage (a French protecting measure for persons with altered judgement)
  • To present obvious cognitive disturbances
  • To have difficulties to read and/or write in French language

结局指标

主要结局

Number of psychiatric comorbidities

时间窗: 5 years

The 10 psychiatric comorbidities explored by the MINI are major depressive episode, (hypo)-maniac episode, 5 anxiety disorders (panic disorder ± agoraphobia, social phobia, obsessional-compulsive disorder, PTSD, generalised anxiety disorder), substance use disorders (alcohol, other psychoactive substances), psychotic disorders, and eating disorders (anorexia nervosa and bulimia).

次要结局

  • Clinical data(5 years)
  • Socio-demographic data(5 years)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (8)

Loading locations...

相似试验

Unknown
不适用
The Efficacy and Safety of Electronic Cigarettes: a 5-year Follow-up StudyCardiovascular DiseasesChronic Obstructive Pulmonary DiseasesCancer of the LungCancer of the BladderCancer of the Stomach
NCT01785537Università degli Studi 'G. d'Annunzio' Chieti e Pescara1,050
招募中
不适用
A multi-center, cross-section, retrospectivestudy of TCM symptome characteristics of atherosclerotic myocardial infarctioAtherosclerotic myocardial infarction
ITMCTR2200005906Zhejiang Chinese Medical University
进行中(未招募)
不适用
A multi-centre, two-staged with interim analysis, parallel, randomised, double blind, placebo-controlled, dose ranging study of the safety, tolerability, and effects on plasma high-density lipoprotein cholesterol (HDLc) of 12 weeks treatment with 2.5mg, 5mg and 10 mg daily doses of GW501516 in subjects with low HDLc
EUCTR2004-000882-36-FIGlaxoSmithKine Research & Development Limited424
进行中(未招募)
不适用
A multi-centre, two-staged with interim analysis, parallel, randomised, double blind, placebo-controlled, dose ranging study of the safety, tolerability, and effects on plasma high-density lipoprotein cholesterol (HDLc) of 12 weeks treatment with 2.5mg, 5mg and 10 mg daily doses of GW501516 in subjects with low HDLcTreatment of dyslipidaemia
EUCTR2004-000882-36-SEGlaxoSmithKine Research & Development Limited424
进行中(未招募)
不适用
A multi-centre, two-staged with interim analysis, parallel, randomised, double blind, placebo-controlled, dose ranging study of the safety, tolerability, and effects on plasma high-density lipoprotein cholesterol (HDLc) of 12 weeks treatment with 2.5mg, 5mg and 10 mg daily doses of GW501516 in subjects with low HDLcTreatment of dyslipidaemia
EUCTR2004-000882-36-DKGlaxoSmithKine Research & Development Limited424